Select Your Location:
Global
France
Italy

Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Tag: Hematologic Malignancies

BeOne is advancing a hematologic malignancy pipeline consisting of novel oral small molecules and monoclonal antibodies. Among these are zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor and BGB-11417, a BCL2 inhibitor, both for the treatment of various B-cell malignancies.

ALPINE (NCT03734016) is a global, randomized, Phase 3 trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Reading
23 May 2025

SEQUOIA (NCT03336333) is a global Phase 3, open-label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Reading
23 May 2025

MAGNOLIA (NCT03846427) is a Phase 2, multicenter, open-label, single-arm trial of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Reading
23 May 2025

ROSEWOOD (NCT03332017) is a global Phase 2, randomized study designed to assess the efficacy and safety of zanubrutinib + obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 lines of therapy.

Reading
23 May 2025

BGB-3111-215 (NCT04116437) is a Phase 2 study evaluating the safety of zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

Reading
23 May 2025